Compare JBLU & MNMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JBLU | MNMD |
|---|---|---|
| Founded | 1998 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Air Freight/Delivery Services | Pharmaceuticals and Biotechnology |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.3B |
| IPO Year | N/A | N/A |
| Metric | JBLU | MNMD |
|---|---|---|
| Price | $5.06 | $13.50 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 9 | 9 |
| Target Price | $4.76 | ★ $30.33 |
| AVG Volume (30 Days) | ★ 16.9M | 2.1M |
| Earning Date | 01-27-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $9,095,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.18 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.34 | $4.70 |
| 52 Week High | $8.31 | $14.81 |
| Indicator | JBLU | MNMD |
|---|---|---|
| Relative Strength Index (RSI) | 63.67 | 56.37 |
| Support Level | $4.51 | $12.85 |
| Resistance Level | $4.70 | $14.81 |
| Average True Range (ATR) | 0.19 | 0.76 |
| MACD | 0.00 | 0.03 |
| Stochastic Oscillator | 86.43 | 49.82 |
JetBlue Airways Corp is a low-cost airline that offers high-quality service, including assigned seating and in-flight entertainment. It served approximately 100 destinations in the United States, the Caribbean and Latin America, Canada, and England. The company currently operates Airbus A321, Airbus A320, Airbus A321neo, and Embraer E190 aircraft types. The company has one operating segment, Air Transportation Services, which provides services in the United States, the Caribbean, Latin America, Canada, and Europe. The majority of revenue is generated from the Domestic & Canada segment.
Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).